| Income Statement | 2025-09-30 | |||
|---|---|---|---|---|
| Revenue | 348 | |||
| Research and development expenses | 30,971 | |||
| Selling, general and administrative expenses | 24,520 | |||
| Total operating expenses | 55,491 | |||
| Operating loss | -55,143 | |||
| Interest income | 6,713 | |||
| Fair value change - warrants | 23,792 | |||
| Loss on disposal of property, plant and equipment | -1 | |||
| Foreign exchange gains/(losses) | 218 | |||
| Loss before tax | -72,005 | |||
| Loss for the period | -72,005 | |||
| Unrealized gain/(loss) on available-for-sale securities, net of tax | 313 | |||
| Total comprehensive loss for the period, net of tax | -71,692 | |||
| Earnings per share, basic | -0.61 | |||
| Earnings per share, diluted | -0.61 | |||
| Weighted average number of shares outstanding, basic | 119,000,266 | |||
| Weighted average number of shares outstanding, diluted | 119,000,266 | |||
NewAmsterdam Pharma Co N.V. (NAMSW)
NewAmsterdam Pharma Co N.V. (NAMSW)